Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

Company Overview

Iovance Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company’s platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells.

Iovance’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy. Treatment involves collecting tumor tissue, expanding the patient’s TILs, administering a lymphodepleting chemotherapy regimen and reinfusing the expanded cells, followed by supportive interleukin-2 therapy.

The company is also evaluating TIL-based therapies in additional solid tumors and cancer-treatment settings, including combination approaches designed to broaden the potential use of its cell therapy platform. Iovance, formerly known as Lion Biotechnologies, changed its name in 2017 and is headquartered in San Carlos, California. Its commercial activities are centered in the United States, while its development programs have involved clinical research conducted across multiple regions.

Key Stats

• Today's Range: $12.92 to $14.21
• 50-Day Range: $4.07 to $14.82
• 52-Week Range: $1.76 to $15.30
• Volume: 18.86 million shs
• Average Volume: 18.62 million shs
• Market Capitalization: $5.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.40
• Consensus Rating: Moderate Buy

Iovance Biotherapeutics Stock Analysis - MarketRank™

Iovance Biotherapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 702nd out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Iovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 9 buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Iovance Biotherapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Iovance Biotherapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($0.45) to ($0.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Iovance Biotherapeutics is -17.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Iovance Biotherapeutics is -17.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Iovance Biotherapeutics has a P/B Ratio of 7.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.86% of the float of Iovance Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iovance Biotherapeutics has a short interest ratio ("days to cover") of 7.43.

Change versus previous month

Short interest in Iovance Biotherapeutics has recently decreased by 1.15%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Iovance Biotherapeutics does not currently pay a dividend.

Dividend Growth

Iovance Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.74

News Sentiment

Iovance Biotherapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 35 news articles for Iovance Biotherapeutics this week, compared to 7 articles on an average week.

Search Interest

70 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.

MarketBeat Follows

16 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 129% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.80% of the stock of Iovance Biotherapeutics is held by insiders.

Percentage Held by Institutions

77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IOVA
• CIK: 1425205
• Web: www.iovance.com
• Phone: (650) 260-7120
• Fax: N/A
• Employees: 975
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Iovance Biotherapeutics: $12.40
• High Price Target: $20.00
• Low Price Target: $6.00
• Potential Upside/Downside: -4.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$390.98 million
• Net Margins: -89.11%
• Pretax Margin: -90.42%
• Return on Equity: -40.51%
• Return on Assets: -31.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.34
• Quick Ratio: 3.82

Sales & Book Value

• Annual Sales: $263.50 million
• Price / Sales: 22.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.76 per share
• Price / Book: 7.36

Miscellaneous

• Outstanding Shares: 452,970,000
• Free Float: 417,639,000
• Market Cap: $5.87 billion
• Optionable: Optionable
• Beta: 0.76